Additionally, our previous clinical trials [22, 23, 27] revealed that intracoronary transfusion of circulation-derived CD34 + cells in patients with end-stage diffuse coronary artery disease who were not candidates for coronary intervention significantly improved heart failure and heart function, mainly through angiogenesis and neovascularization. The gene discussed is CD34; the disease is heart failure.